Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 4;87(21):14026-14036.
doi: 10.1021/acs.joc.2c01651. Epub 2022 Oct 20.

Chemoselective Solution- and Solid-Phase Synthesis of Disulfide-Linked Glycopeptides

Affiliations

Chemoselective Solution- and Solid-Phase Synthesis of Disulfide-Linked Glycopeptides

Katreen A F Banisalman et al. J Org Chem. .

Abstract

Glycosylation of peptides and proteins is a widely employed strategy to mimic important post-translational modifications or to modulate the physicochemical properties of peptides to enhance their delivery. Furthermore, glycosylation via a sulfur atom imparts increased chemical and metabolic stability to the resulting glycoconjugates. Herein, we report a simple and chemoselective procedure to prepare disulfide-linked glycopeptides. Acetate-protected glycosylsulfenyl hydrazines are shown to be highly reactive with the thiol group of cysteine residues within peptides, both in solution and as part of conventional solid-phase peptide synthesis protocols. The efficiency of this glycosylation methodology with unprotected carbohydrates is also demonstrated, which avoids the need for deprotection steps and further extends its utility, with disulfide-linked glycopeptides produced in excellent yields. Given the importance of glycosylated peptides in structural glycobiology, pharmacology, and therapeutics, the methodology outlined provides easy access to disulfide-linked glycopeptides as molecules with multiple biological applications.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Scheme 1
Scheme 1. One-Pot Protocol to Prepare Disulfide-Linked Glycopeptides
Scheme 2
Scheme 2. Two-Pot Protocol to Access Disulfide-Linked Glycopeptide
Scheme 3
Scheme 3. Solid-Phase Disulfide-Linked-Glycosylation of Peptides
Scheme 4
Scheme 4. Solid-Phase Glycosylation of Fmoc-Met-Pro-Ala-Cys-Gly-Ser-Ser-OH (Yielding Compounds 3g and 8g) and H2N-Tyr-Thr-Gly-Phe-Leu-Cys-Leu-OH (Yielding Compounds 3m and 8m)
Synthetic conditions: (i) CH2Cl2/TFA/TIS 95:2:3, 3 cycles of 10 min; (ii) 5 or 7 (2.5 equiv), N,N-diisopropylethylamine (DIPEA) (1 equiv), dimethylformamide (DMF) 2 cycles × 30 min; (iii) TFA/TIS/water 95:2.5:2.5, 4 h.
Figure 1
Figure 1
13C NMR spectra recorded in CD3OD. (A) 13C NMR spectrum of d-thioglucose sodium salt; (B) 13C NMR spectrum of reaction of d-thioglucose sodium salt with dilute deuterated methanolic DEAD (2.0 equiv) (instant reaction); (C) 13C NMR spectrum after addition of PhSH (2.0 equiv) (1 h).
Scheme 5
Scheme 5. Schematic Representation of Synthesis of Unprotected Glycosyl Disulfide 16
Scheme 6
Scheme 6. Synthesis of Symmetrical Dithiosaccharides
Figure 2
Figure 2
High-performance liquid chromatography (HPLC) chromatogram (λ = 254 nm) of peptide 2g (green), and crude reaction mixtures after reaction with symmetrical glycosyl disulfide 17 (yielding compound 23g, purple), and 19 (yielding compound 24g, black), respectively.

Similar articles

Cited by

References

    1. Banting F. G.; Best C. H.; Collip J. B.; Campbell W. R.; Fletcher A. A. Pancreatic Extracts in the Treatment of Diabetes Mellitus. Can. Med. Assoc. J. 1922, 12, 141–146. - PMC - PubMed
    1. Lau J. L.; Dunn M. K. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg. Med. Chem. 2018, 26, 2700–2707. 10.1016/j.bmc.2017.06.052. - DOI - PubMed
    1. Fosgerau K.; Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today 2015, 20, 122–128. 10.1016/j.drudis.2014.10.003. - DOI - PubMed
    1. Usmani S. S.; Bedi G.; Samuel J. S.; Singh S.; Kalra S.; Kumar P.; Ahuja A. A.; Sharma M.; Gautam A.; Raghava G. P. S. THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS One 2017, 12, e018174810.1371/journal.pone.0181748. - DOI - PMC - PubMed
    1. Mathur D.; Prakash S.; Anand P.; Kaur H.; Agrawal P.; Mehta A.; Kumar R.; Singh S.; Raghava G. P. S. PEPlife: A Repository of the Half-life of Peptides. Sci. Rep. 2016, 6, 3661710.1038/srep36617. - DOI - PMC - PubMed

Publication types